Can a new pill stop liver damage in hepatitis b patients?
NCT ID NCT07412236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called hydronidone in people with liver scarring (fibrosis) from chronic hepatitis B. About 1,200 adults will take either hydronidone or a placebo, along with standard antiviral therapy, for up to 5 years. The goal is to see if hydronidone can prevent serious liver problems like cirrhosis, liver cancer, or the need for a transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact